Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of BILR 355/r and Combivir
NCT02256774Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2004
- Primary completion
- May 2005
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of BILR 355 in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over one dosing interval at steady state and Maximum measured concentration of the analyte in plasma at steady state. Started Oct 2004; status: completed.
02
Drugs
BILR 355
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02256774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02256774.